ATE316529T1 - Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns) - Google Patents
Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns)Info
- Publication number
- ATE316529T1 ATE316529T1 AT98203154T AT98203154T ATE316529T1 AT E316529 T1 ATE316529 T1 AT E316529T1 AT 98203154 T AT98203154 T AT 98203154T AT 98203154 T AT98203154 T AT 98203154T AT E316529 T1 ATE316529 T1 AT E316529T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridylmethylpiperazine
- cns
- diseases
- substituted
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202950 | 1997-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE316529T1 true ATE316529T1 (de) | 2006-02-15 |
Family
ID=8228755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98203154T ATE316529T1 (de) | 1997-09-24 | 1998-09-21 | Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns) |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6090812A (de) |
| EP (1) | EP0908458B1 (de) |
| JP (1) | JP4191826B2 (de) |
| KR (1) | KR100632188B1 (de) |
| CN (1) | CN1093857C (de) |
| AR (1) | AR017127A1 (de) |
| AT (1) | ATE316529T1 (de) |
| AU (1) | AU733526B2 (de) |
| BR (1) | BR9803497A (de) |
| CA (1) | CA2247734C (de) |
| CY (1) | CY1107494T1 (de) |
| CZ (1) | CZ296741B6 (de) |
| DE (1) | DE69833297T2 (de) |
| DK (1) | DK0908458T3 (de) |
| DZ (1) | DZ2613A1 (de) |
| ES (1) | ES2255127T3 (de) |
| HU (1) | HU227422B1 (de) |
| ID (1) | ID20895A (de) |
| IL (1) | IL126295A (de) |
| NO (1) | NO312835B1 (de) |
| NZ (1) | NZ331984A (de) |
| PL (1) | PL190622B1 (de) |
| PT (1) | PT908458E (de) |
| RU (1) | RU2197488C2 (de) |
| SI (1) | SI0908458T1 (de) |
| SK (1) | SK285205B6 (de) |
| TR (1) | TR199801866A1 (de) |
| TW (1) | TW530054B (de) |
| UA (1) | UA66756C2 (de) |
| ZA (1) | ZA988749B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200994B1 (en) | 1999-01-07 | 2001-03-13 | American Home Products Corp | 1,4-Disubstituted cyclohexane derivatives for the treatment of depression |
| ES2182775T3 (es) * | 1999-01-07 | 2003-03-16 | Wyeth Corp | Derivados de ciclohexano 1,4-disustituidos para el tratamiento de la depresion. |
| DE10005150A1 (de) | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| ATE255578T1 (de) * | 2000-05-12 | 2003-12-15 | Solvay Pharm Bv | Piperazin- und piperidinverbindungen |
| DE10115922A1 (de) * | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DK1408976T5 (da) * | 2001-07-20 | 2011-01-10 | Psychogenics Inc | Behandling af ADHD (Attention deficit hyperactivity disorder) |
| US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| US20070275977A1 (en) * | 2006-05-02 | 2007-11-29 | Van Aar Marcel P | N-oxides of pyridylmethyl -piperazine and -piperidine derivatives |
| EP2024363B1 (de) | 2006-05-02 | 2012-08-01 | Abbott Healthcare Products B.V. | N-oxide von pyridylmethylpiperazin- und piperidinderivaten |
| US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| WO2011088838A1 (en) | 2010-01-25 | 2011-07-28 | H. Lundbeck A/S | Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| US10710980B2 (en) | 2016-07-20 | 2020-07-14 | Novartis Ag | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
| KR101665971B1 (ko) | 2016-08-10 | 2016-10-13 | (주)글로벌 로보틱스 | 차량용 발포패드 부착장치 |
| JP7717065B2 (ja) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Alk2阻害剤及びjak2阻害剤を含む併用療法 |
| AU2021292484A1 (en) | 2020-06-16 | 2023-01-19 | Incyte Corporation | ALK2 inhibitors for the treatment of anemia |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0185429A1 (de) * | 1984-12-21 | 1986-06-25 | Duphar International Research B.V | Bizyklische Piperazine |
| DE3586794T2 (de) | 1984-12-21 | 1993-05-27 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
| EP0241053B1 (de) * | 1986-02-27 | 1992-11-11 | Duphar International Research B.V | Aryl-substituierte(N-piperidinyl)methyl und (N-piperazinyl)methylazole mit antipsychotischer Wirkung |
| EP0508347A1 (de) * | 1991-04-10 | 1992-10-14 | Hoechst Aktiengesellschaft | 5,7-Dihydroxy-2-Methyl-8-[4-(3-Hydroxy-1-(1-Propyl))Piperidinyl]-4H-1-Benzopyran-4-on, seine Herstellung und Verwendung |
| NZ240863A (en) * | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| JPH05262765A (ja) * | 1992-03-18 | 1993-10-12 | Sumitomo Chem Co Ltd | ベンゾフラン誘導体およびそれを有効成分とする除草剤 |
| FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| US5332732A (en) * | 1992-09-11 | 1994-07-26 | Mcneilab, Inc. | Thiophene and pyridine antipsychotic agents |
| US5436246A (en) * | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
| RU2118322C1 (ru) * | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
| GB9314758D0 (en) * | 1993-07-16 | 1993-08-25 | Wyeth John & Brother Ltd | Heterocyclic derivatives |
| EP0650964A1 (de) | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate |
| DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
| EP0839144B1 (de) * | 1995-07-13 | 2001-09-19 | Knoll GmbH | Piperazin-derivate als heilmittel |
| ES2271967T3 (es) * | 1996-03-29 | 2007-04-16 | Duphar International Research B.V | Compuestos de piperazina y piperidina. |
| DE19637237A1 (de) * | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
-
1998
- 1998-09-11 TW TW087115179A patent/TW530054B/zh not_active IP Right Cessation
- 1998-09-18 IL IL12629598A patent/IL126295A/xx not_active IP Right Cessation
- 1998-09-21 TR TR1998/01866A patent/TR199801866A1/xx unknown
- 1998-09-21 HU HU9802129A patent/HU227422B1/hu not_active IP Right Cessation
- 1998-09-21 EP EP98203154A patent/EP0908458B1/de not_active Expired - Lifetime
- 1998-09-21 DK DK98203154T patent/DK0908458T3/da active
- 1998-09-21 CN CN98119652A patent/CN1093857C/zh not_active Expired - Fee Related
- 1998-09-21 NZ NZ331984A patent/NZ331984A/en not_active IP Right Cessation
- 1998-09-21 AU AU86079/98A patent/AU733526B2/en not_active Ceased
- 1998-09-21 NO NO19984380A patent/NO312835B1/no not_active IP Right Cessation
- 1998-09-21 PT PT98203154T patent/PT908458E/pt unknown
- 1998-09-21 RU RU98117621/04A patent/RU2197488C2/ru not_active IP Right Cessation
- 1998-09-21 JP JP28357898A patent/JP4191826B2/ja not_active Expired - Lifetime
- 1998-09-21 AR ARP980104704A patent/AR017127A1/es active IP Right Grant
- 1998-09-21 AT AT98203154T patent/ATE316529T1/de active
- 1998-09-21 CZ CZ0303098A patent/CZ296741B6/cs not_active IP Right Cessation
- 1998-09-21 KR KR1019980038929A patent/KR100632188B1/ko not_active Expired - Fee Related
- 1998-09-21 PL PL98328754A patent/PL190622B1/pl not_active IP Right Cessation
- 1998-09-21 BR BR9803497-9A patent/BR9803497A/pt not_active IP Right Cessation
- 1998-09-21 DE DE69833297T patent/DE69833297T2/de not_active Expired - Lifetime
- 1998-09-21 ES ES98203154T patent/ES2255127T3/es not_active Expired - Lifetime
- 1998-09-21 SI SI9830822T patent/SI0908458T1/sl unknown
- 1998-09-21 CA CA002247734A patent/CA2247734C/en not_active Expired - Fee Related
- 1998-09-21 ID IDP981269A patent/ID20895A/id unknown
- 1998-09-21 SK SK1294-98A patent/SK285205B6/sk not_active IP Right Cessation
- 1998-09-22 DZ DZ980223A patent/DZ2613A1/xx active
- 1998-09-22 US US09/158,520 patent/US6090812A/en not_active Ceased
- 1998-09-22 UA UA98094970A patent/UA66756C2/uk unknown
- 1998-09-23 ZA ZA988749A patent/ZA988749B/xx unknown
-
2006
- 2006-04-07 CY CY20061100484T patent/CY1107494T1/el unknown
-
2008
- 2008-04-18 US US12/081,710 patent/USRE41425E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE316529T1 (de) | Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns) | |
| ATE258549T1 (de) | Oxazolidindion-derivate, ihre herstellung und verwendung | |
| DE69836752D1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
| DE69623992D1 (de) | Derivate von dolestatin, deren herstellung und verwendung | |
| DE69720463D1 (de) | Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen | |
| ATE432940T1 (de) | Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel | |
| ATE204754T1 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
| DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
| DE69212620D1 (de) | Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie | |
| ATE215373T1 (de) | 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss | |
| DE69824576D1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
| DE69027170D1 (de) | Uracilderivate, ihre Herstellung und ihre Verwendung | |
| DE69734296D1 (de) | Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b | |
| DE69716896D1 (de) | Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression | |
| DE69912670D1 (de) | Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen | |
| ATE304542T1 (de) | Substituierte (1,3-bis(cyclohexylmethyl)-1,2,3,6- tetrahydro-2,6-dioxo-9h-purin-8yl)phenyl derivate,deren herstellung und deren verwendung in der behandlung von entzündungen und immunkrankheiten | |
| DE69534632T2 (de) | Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit | |
| DE59711704D1 (de) | Neue carbonsäurederivate, ihre herstellung und verwendung | |
| DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
| PT85396B (de) | Neue 1,4-benzodiazepine ihre herstellung und verwendung | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
| DE69611303D1 (de) | Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung | |
| DE69738320D1 (de) | Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch | |
| DE59501950D1 (de) | Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0908458 Country of ref document: EP |